![[icon] Healthcare IT](https://asset.fujifilm.com/www/th/files/2024-08/56680c6fdbf34936593e85134920c43a/healthcare-it.svg)
![[icon] X-ray](https://asset.fujifilm.com/www/th/files/2024-08/7526d1101b64112bf22b55db55efaa57/x-ray.svg)
![[icon] Ultrasound](https://asset.fujifilm.com/www/th/files/2024-08/1dda2d2eb91f3c86fa66f03f9c819a82/ultrasound.svg)
![[icon] Endoscopy](https://asset.fujifilm.com/www/th/files/2024-08/05f6b3f71db56279cab3348b30a4ba0b/endoscopy.svg)
![[icon] In Vitro Diagnostics](https://asset.fujifilm.com/www/th/files/2024-08/9e91ed0a102839a6882a0de74d502cee/ivd.svg)
![[icon] Veterinary Medicine](https://asset.fujifilm.com/www/th/files/2024-08/6a151464d073132ebaf32502ba57c4df/veterinary.svg)
![[icon] MRI and CT](https://asset.fujifilm.com/www/th/files/2024-08/0bb04b1be5a01844c53173c0ccabe874/mri-and-ct.svg)
![[icon] Inkjet Solutions](https://asset.fujifilm.com/www/th/files/2024-08/73d9b8524c59e74c542df1f23c4f07ce/inkjet-solutions.svg)
![[icon] Office Solutions](https://asset.fujifilm.com/www/th/files/2024-08/5b47599c8e70a8fe60ffa0a98c41a514/office.svg)
![[icon] Graphic Arts & Printing](https://asset.fujifilm.com/www/th/files/2024-08/b7dca46beab06d8bdac1897bd5621c06/graphic.svg)
![[icon] Photofinishing Products](https://asset.fujifilm.com/www/th/files/2024-08/7ae7e1b29f74fc1b562542b0d7c87b2e/photofinishing.svg)
![[icon] Optical Devices](https://asset.fujifilm.com/www/th/files/2024-08/a6203f1389ec8eb7ee25055419384f25/optical-devices.svg)
![[icon] Cine & Broadcast Products](https://asset.fujifilm.com/www/th/files/2024-08/8d74351df62db4d1d4b9779ce282e709/film-and-broadcast.svg)
![[icon] Security Protections](https://asset.fujifilm.com/www/th/files/2024-08/020de2cfc6945ce00c20063e32463c2c/security.svg)
![[icon] Manufacturing Process](https://asset.fujifilm.com/www/th/files/2024-08/d84916c806eb5d08efbaa4fce95c9d15/manufacturing-process.svg)
![[icon] Inspectional Products](https://asset.fujifilm.com/www/th/files/2024-08/7a66c0f5baac60152d24f069082a63fa/inspection.svg)
![[icon] Data Management](https://asset.fujifilm.com/www/th/files/2024-08/301ac4f37d11d528a63fd6f7d050d817/data-management.svg)
![[icon] Materials](https://asset.fujifilm.com/www/th/files/2024-08/163c2f189d153cf287f7f0bcf783864c/materials.svg)
Bangkok, 20 August 2024 — Fujifilm reinforces its position as a leading one-stop, total healthcare solution provider by showcasing its "Total Screening Solution" at the Thailand Wellness and Healthcare Expo 2024 from 16 – 18 August 2024 held at BITEC (Bangkok International Trade & Exhibition Centre. Fujifilm's innovative lineup includes medical screening equipment for detecting comprehensive women's health issues, liver cancer and colorectal cancer, addressing major health challenges faced by both the Thai and global populations. The exhibition emphasizes advanced medical imaging solutions and comprehensive AI-powered systems, aimed at enhancing diagnostic accuracy, enabling timely treatment, and improving patients' quality of life and well-being. The Thailand Wellness and Healthcare Expo 2024 gathered leading providers in healthcare, the medical industry, digital health, and wellness to explore the latest trends and showcase breakthrough technologies that advance well-being in Thailand and worldwide.
Mr. So Maruo, Managing Director of FUJIFILM (Thailand) Ltd., said, “Realizing medical innovations can enhance the country's healthcare services, Fujifilm is dedicated to advancing our one-stop, total healthcare solution, leveraging our unrivaled expertise and over 80 years of experience in medical imaging. Fujifilm’s strength lies in integrating these solutions with AI and IT, contributing to early and accurate disease detection, and significantly reducing clinicians’ workloads. Early detection is crucial for timely treatment, yet it remains a challenge in many countries. To tackle this issue, Fujifilm is committed to continuously innovating medical diagnostic systems. Our Total Screening Solution for colon, liver, and women’s health allows hospitals to treat more patients, increasing access to healthcare and improving lives globally. This focus on healthcare and commitment to developing breakthrough screening equipment aligns with Fujifilm Group’s Purpose: Giving our world more smiles.”
Fujifilm addresses global health challenges with its Total Screening Solution, which synchronizes with AI and IT systems to provide accurate and timely results for doctors and medical personnel.
Fujifilm’s comprehensive women's healthcare screening solutions are now unified under the brand INNOMUSE, inspired by “innovation” and “muse.” This includes the AMULET Innovality digital mammography system and the Arietta 850 DeepInsight digital ultrasound system. INNOMUSE encompasses advanced technologies designed to address various aspects of women's health, including breast imaging, obstetrics, gynecology, and bone health.
Currently, breast cancer is the leading cause of death among women. Fujifilm hopes its medical advancements and technology will enable all Thai women to easily access screening services. Early detection increases the chances of successful treatment and reduces mortality risk. The AMULET Innovality provides high-resolution imaging for accurate breast cancer detection, while the Arietta 850 DeepInsight, a premium diagnostic ultrasound system, delivers detailed diagnostics with excellent noise reduction, stable penetration, and high spatial resolution using DeepInsight technology. Both systems integrate AI to enhance diagnostic precision and efficiency.
The severity of the liver cancer situation in Thailand is highlighted by alarming statistics from the Thailand Cancer Registry by the National Cancer Institute, with over 140,000 new cases reported annually.1 Fujifilm’s total screening solution for liver cancer, led by the μTASWako i30, is a game-changer in hepatocellular carcinoma detection. This fully automated microfluidic-based immunoanalyzer solution tailored for HCC diagnosis is known for its exceptional efficiency and accuracy. Capable of delivering a blood result in just 9 minutes and processing up to 25 results per hour, the μTASWako i30 enhances the speed and reliability of liver cancer screenings. By providing precise and timely diagnostics, this technology supports doctors in making quicker and more accurate treatment decisions, significantly improving patient outcomes and revolutionizing the approach to liver cancer detection and management.
In the realm of colorectal cancer screening, Fujifilm ELUXEO 7000 system, featuring the BL-7000 and VP-7000 processors, combined with the AI-powered CADEYE technology, stands out as a pioneering solution. The ELUXEO 7000 system converts image signals from endoscopes, utilizing LCI and BLI technologies to detect and analyze signs of disease in the colon. When paired with CADEYE, this system identifies subtle disease markers that might be missed by the human eye, thus enhancing diagnostic accuracy and efficiency. Fujifilm aims to promote widespread colonoscopy screening, especially for individuals aged 45 to 70 with positive FIT test (Fecal Immunochemical Test) results. This initiative will increase access to early detection and treatment, particularly in remote and densely populated areas, reducing colorectal cancer morbidity and mortality rates.
Fujifilm’s Total Screening Solution, showcased at the Thailand Wellness and Healthcare Expo 2024, exemplifies its mission to address global health challenges through innovation. By focusing on pioneering medical technologies and comprehensive screening solutions, Fujifilm continues to bring more smiles to the world, reaffirming its commitment to creating a healthier future for all.
Reference
1. National Cancer Conference 2023 Thailand’s cancer statistics: https://www.hfocus.org/content/2023/02/27095